Diagnostic value of serum levels of acylated ghrelin and nesfatin-1 in adult patients with primary epilepsy

doi:10.3877/cma.j.issn.2095-655X.2017.02.011

Abstract

Abstract:

Objective

To study the serum levels of acylated ghrelin(AG)and nesfatin-1 in adult patients with primary epilepsy in the pretreatment period and six months after carbamazepine (CBZ) or valproic acid(VPA) therapy.

Methods

Fifty adult patients with primary epilepsy [30 with secondary generalized epilepsy (SGE), 20 with primary generalized epilepsy (PGE)] and 20 control patients were included in this study.Serum levels of AG and nesfatin-1 were measured in these groups in the pretreatment period and six months after treatment.

Results

Serum level of AG in control group was (42.49±8.24) ng/L, pretherapy serum level of AG in SGE (32.67±5.64)ng/L was lower than that in control group (t=2.08, P<0.05). Post-CBZ therapy serum level of AG (54.31±7.91)ng/L was higher than that in pretherapy (t=2.80, P<0.05). Pretherapy serum level of AG in PGE (31.56±6.32)ng/L was lower than that in control group(t=2.09, P<0.05), post-VPA therapy serum level of AG (51.37±7.56)ng/L was higher than that in pretherapy(t=3.22, P<0.05). Serum level of nesfatin-1 in control group was (0.66±0.02)μg/L.Pretherapy serum level of nesfatin-1 in SGE [(6.57±0.93)μg/L] was higher than that in control group(t=2.18, P<0.05), post-CBZ therapy serum level of nesfatin-1 [(2.74±0.56)μg/L] was also higher than that in control group(t=2.05, P<0.05). Pretherapy serum level of nesfatin-1 in PGE (9.04±1.32)μg/L was higher than that in control group (t=3.83, P<0.05), post-VPA therapy serum level of nesfatin-1(3.28±0.43)μg/L was also higher than that in control group (t=2.24, P<0.05).

Conclusion

AG may have protective effects on neurons and have antiepilepsy effects, nesfatin-1 may serve as biomarker for the diagnosis of primary epilepsy.

Key words: Epilepsy, Neuropeptides, Carbamazepine, Valproic acid

Min Xia, Dong Liu, Yanling Wang, Xu Chu, Qingxia Kong. Diagnostic value of serum levels of acylated ghrelin and nesfatin-1 in adult patients with primary epilepsy[J]. Chinese Journal of Diagnostics(Electronic Edition), 2017, 05(02): 120-123.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2017.02.011

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2017/V05/I02/120

Figures/Tables 1

References 19

[1]	Pack A. Effects of treatment on endocrine function in patients with epilepsy[J]. Curr Treat Options Neurol, 2005, 7(4): 273-280.
[2]	Greco R,Latini G,Chiarelli F, et al.Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid[J]. Neurology, 2005, 65(11): 1808-1809.
[3]	Oh-I S,Shimizu H,Satoh T, et al.Identication of nesfatin-1 as a satiety molecule in the hypothalamus[J]. Nature, 2006, 443(7112): 709-712.
[4]	Blume WT,Lüders HO,Mizrahi E, et al.Glossary of descriptive terminology for ictal semiology：report of the ILAE task force on classification and terminology[J]. Epilepisa, 2001, 42(9): 1212-1218.
[5]	Meierkord H,Shorvon S,Lightman SL.Plasma concentrations of prolactin, noradrenaline, vasopressin and oxytocin during and after a prolonged epileptic seizure[J]. Acta Neurol Scand, 1994, 90(2): 73-77.
[6]	张军臣,张冉,张广宁, 等. 槲皮素对颞叶癫痫大鼠学习记忆能力的影响[J/CD]. 中华诊断学电子杂志, 2016, 4(2): 131-135.
[7]	Duckert P,Brunak S,Blom N. Prediction of proprotein convertase cleavage sites [J]. Protein Eng Des Sel, 2004, 17(1): 107-112.
[8]	Bali A,Singh N,Jaggi AS.Neuropeptides as therapeutic targets to combat stress-associated behavioral and neuroendocrinological effects[J]. CNS Neurol Disord Drug Targets, 2014, 13(2): 347-368.
[9]	Aydin S,Dag E,Ozkan Y, et al.Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients：hormonal changes can have a major effect on seizure disorders[J]. Mol Cell Biochem, 2009, 328(1-2): 49-56.
[10]	Bednarek MA,Feighner SD,Pong SS, et al.Structure-function studies on the new growth hormone-releasing peptide, ghrelin：minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1α[J]. J Med Chen, 2000, 43(23): 4370-4376.
[11]	Clynen E,Swijsen A,Raijmakers M, et al.Neuropeptides as Targets for the Development of Anticonvulsant Drugs[J]. Mol Neurobiol, 2014, 50(2): 626-646.
[12]	Ataie Z,Golzar MG,Babri Sh, et al.Does ghrelin level change after epileptic seizure in rats？[J]. Seizure, 2011, 20(4): 347-349.
[13]	Taskin E,Atli B,Kilic M, et al.Serum, Urine, and saliva levels of ghrelin and obestatin pre-and post-treatment in pediatric epilepsy[J]. Pediatric Neurol, 2014, 51(3): 365-369.
[14]	Aydin S,Dag E,Ozkan Y, et al.Time-dependent changes in the serum levels of prolactin, nesfatin-1 and ghrelin as a marker of epileptic attacks young male patients[J]. Peptides, 2011, 32(6): 1276-1280.
[15]	El Eter E,Al Tuwaijiri A,Hagar H, et al.In vivo and in vitro antioxidant activity of ghrelin：attenuation of gastric ischemic injury in the rat[J]. J Gastroenterol Hepatol, 2007, 22(11): 1791-1799.
[16]	Pan W,Tu H,Kastin AJ.Differential BBB interactions of three ingestive peptides：obestatin, ghrelin, and adiponectin[J]. Peptides, 2006, 27(4): 911-916.
[17]	Obay BD,Tasdemir E,Tümer C, et al.Antiepileptic effects of ghrelin on pentylenetetrazole-induced seizures in rats[J]. Peptides, 2007, 28(6): 1214-1219.
[18]	Jeanelle Portelli,Yvette Michotte,Ilse Smolders.Ghrelin：an emerging new anticonvulsant neuropeptide[J]. Epilepsia, 2012, 53(4): 585-595.
[19]	Zhang R,Yang G,Wang Q, et al.Acylated ghrelin protects hippocampal neurons in pilocarpine-induced seizures of immature rats by inhibiting cell apoptosis[J]. Mol Biol Rep, 2013, 40(1): 51-58.

检测指标	对照组(n＝20)	SGE组(n＝30)	PGE组(n＝20)	F值	P值
年龄(岁)	30.80±4.23	31.77±5.64	29.38±3.90	1.48	>0.05
BMI(kg/m²)	23.63±2.67	23.70±4.88	23.00±4.08	0.19	>0.05
Glu(mmol/L)	5.19±0.53	4.62±0.70	4.88±1.22	1.74	>0.05
TC(mmol/L)	4.53±0.41	4.50±0.77	4.38±0.68	0.33	>0.05
TG(mmol/L)	1.47±0.30	1.36±0.54	1.45±0.57	0.36	>0.05
LDL(mmol/L)	2.29±0.56	2.34±0.60	1.98±0.52	2.62	>0.05
C-肽(nmol/L)	0.78±0.22	0.75±0.28	0.66±0.13	1.63	>0.05

检测指标	对照组(n＝20)	SGE组(n＝30)	PGE组(n＝20)	F值	P值
年龄(岁)	30.80±4.23	31.77±5.64	29.38±3.90	1.48	>0.05
BMI(kg/m²)	23.63±2.67	23.70±4.88	23.00±4.08	0.19	>0.05
Glu(mmol/L)	5.19±0.53	4.62±0.70	4.88±1.22	1.74	>0.05
TC(mmol/L)	4.53±0.41	4.50±0.77	4.38±0.68	0.33	>0.05
TG(mmol/L)	1.47±0.30	1.36±0.54	1.45±0.57	0.36	>0.05
LDL(mmol/L)	2.29±0.56	2.34±0.60	1.98±0.52	2.62	>0.05
C-肽(nmol/L)	0.78±0.22	0.75±0.28	0.66±0.13	1.63	>0.05

Please choose a citation manager

Content to export